Skip to main content
SpringerLink
Log in

In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous

  • Original Article
  • Published:
Virchows Archiv Aims and scope Submit manuscript

Abstract

We examined somatostatin receptor type 2A (SSTR2A) expression in primary and metastatic small intestinal neuroendocrine tumors (SI-NETs). We retrieved 156 liver metastases from 26 patients (10 males, 16 females) who had two or more liver lesions resected. A representative formalin-fixed paraffin-embedded section of tumor tissue from each liver metastasis and from the primary tumor, when available, were immunohistochemically stained for SSTR2A. SSTR2A expression was evaluated by the Her2/neu-scoring system and the scoring system proposed by Volante et al. Based on the Her2/neu-scoring system, moderate to strong SSTR2A expression was observed in 121 of 156 (78%) liver metastases. In 15 (58%) subjects, all liver metastases showed moderate to strong SSTR2A expression, whereas in 11 (42%) one or more liver tumors had weak or no expression. Of the 16 stained primaries, 11 (69%) showed heterogeneous SSTR2A expression. The corresponding liver metastases showed only weak to no expression in one, moderate to strong in five, and both weak to no and moderate to strong expression in five of the 11 cases. Using the Volante scoring system, no tumor was scored 0 (0%), two were scored 1 (1%), 38 were scored 2 (24%), and 116 were scored 3 (74%). No statistically significant association was observed between SSTR2A expression and Ki67 index (p = 0.56). Fifteen of 18 (83%) metastatic tumors with a Ki67 index >20% showed moderate to strong SSTR2A. Most liver tumors with weak SSTR2A expression or an IHC score of 2 were detected by OctreoScan. SSTR2A expression in liver metastases of SI-NETs can be variable, even between lesions in the same patient. Expression in metastatic lesions is not always similar to that in the primary tumor. SSTR2A expression is not associated with the Ki67 index.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB (1995) The somatostatin receptor family. Life Sci 57:1249–1265

    Article  CAS  PubMed  Google Scholar 

  2. Jais P, Terris B, Ruszniewski P, LeRomancer M, Reyl-Desmars F, Vissuzaine C, Cadiot G, Mignon M, Lewin MJ (1997) Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Investig 27:639–644

    Article  CAS  Google Scholar 

  3. Papotti M, Bongiovanni M, Volante M, Allia E, Landolfi S, Helboe L, Schindler M, Cole SL, Bussolati G (2002) Expression of somatostatin receptor types 1-5 in 81 cases of gastrointestinal and pancreatic endocrine tumors. A correlative immunohistochemical and reverse-transcriptase polymerase chain reaction analysis. Virchows Arch 440:461–475

    Article  CAS  PubMed  Google Scholar 

  4. Kubota A, Yamada Y, Kagimoto S, Shimatsu A, Imamura M, Tsuda K, Imura H, Seino S, Seino Y (1994) Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93:1321–1325

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Reubi JC, Schaer JC, Waser B, Mengod G (1994) Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 54:3455–3459

    CAS  PubMed  Google Scholar 

  6. Kimura N, Pilichowska M, Date F, Kimura I, Schindler M (1999) Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res 5:3483–3487

    CAS  PubMed  Google Scholar 

  7. Reubi JC, Waser B (2003) Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 30:781–793

    Article  CAS  PubMed  Google Scholar 

  8. Kagimoto S, Yamada Y, Kubota A, Someya Y, Ihara Y, Yasuda K, Kozasa T, Imura H, Seino S, Seino Y (1994) Human somatostatin receptor, SSTR2, is coupled to adenylyl cyclase in the presence of Gi alpha 1 protein. Biochem Biophys Res Commun 202:1188–1195

    Article  CAS  PubMed  Google Scholar 

  9. Modlin IM, Lye KD, Kidd M (2003) A 5-decade analysis of 13,715 carcinoid tumors. Cancer 97:934–959

    Article  PubMed  Google Scholar 

  10. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, Abdalla EK, Fleming JB, Vauthey JN, Rashid A, Evan DB (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072

    Article  PubMed  Google Scholar 

  11. Caplin ME, Pavel M, Ruszniewski P (2014) Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 371:1556–1557

    Article  PubMed  Google Scholar 

  12. Wynick D, Anderson JV, Williams SJ, Bloom SR (1989) Resistance of metastatic pancreatic endocrine tumours after long-term treatment with the somatostatin analogue octreotide (SMS 201-995). Clin Endocrinol 30:385–388

    Article  CAS  Google Scholar 

  13. Reubi JC, Kvols LK, Waser B, Nagorney DM, Heitz PU, Charboneau JW, Reading CC, Moertel C (1990) Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 50:5969–5977

    CAS  PubMed  Google Scholar 

  14. Kvols LK, Buck M, Moertel CG, Schutt AJ, Rubin J, O'Connell MJ, Hahn RG (1987) Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med 107:162–168

    Article  CAS  PubMed  Google Scholar 

  15. Kvols LK, Moertel CG, O'Connell MJ, Schutt AJ, Rubin J, Hahn RG (1986) Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 315:663–666

    Article  CAS  PubMed  Google Scholar 

  16. Gardner-Roehnelt NM (2012) Update on the management of neuroendocrine tumors: focus on somatostatin antitumor effects. Clin J Oncol Nurs 16:56–64

    Article  PubMed  Google Scholar 

  17. Laznicek M, Laznickova A, Maecke HR (2012) Receptor affinity and preclinical biodistribution of radiolabeled somatostatin analogs. Anticancer Res 32:761–766

    CAS  PubMed  Google Scholar 

  18. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, Macke HR (2000) Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 27:273–282

    Article  CAS  PubMed  Google Scholar 

  19. Janson ET, Gobl A, Kalkner KM, Oberg K (1996) A comparison between the efficacy of somatostatin receptor scintigraphy and that of in situ hybridization for somatostatin receptor subtype 2 messenger RNA to predict therapeutic outcome in carcinoid patients. Cancer Res 56:2561–2565

    CAS  PubMed  Google Scholar 

  20. Bakker WH, Krenning EP, Reubi JC, Breeman WA, Setyono-Han B, de Jong M, Kooij PP, Bruns C, van Hagen PM, Marbach P et al (1991) In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats. Life Sci 49:1593–1601

    Article  CAS  PubMed  Google Scholar 

  21. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC et al (1993) Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20:716–731

    Article  CAS  PubMed  Google Scholar 

  22. Maecke HR, Reubi JC (2011) Somatostatin receptors as targets for nuclear medicine imaging and radionuclide treatment. J Nucl Med 52:841–844

    Article  CAS  PubMed  Google Scholar 

  23. Ambrosini V, Fani M, Fanti S, Forrer F, Maecke HR (2011) Radiopeptide imaging and therapy in Europe. J Nucl Med 52(Suppl 2):42S–55S

    Article  CAS  PubMed  Google Scholar 

  24. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V (2012) Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42:80–87

    Article  CAS  PubMed  Google Scholar 

  25. Sharma N, Naraev BG, Engelman EG, Zimmerman MB, Bushnell DL, Jr., O'Dorisio TM, O'Dorisio MS, Menda Y, Muller-Brand J, Howe JR et al. (2016) Peptide receptor radionuclide therapy outcomes in a North American cohort with metastatic well-differentiated neuroendocrine tumors. Pancreas.

  26. Yalchin M, Oliveira A, Theocharidou E, Pencharz D, Navalkissoor S, Quigley AM, Walker M, Caplin M, Toumpanakis C (2016) The impact of radiological response to peptide receptor radionuclide therapy on overall survival in patients with metastatic midgut neuroendocrine tumors. Clin Nucl Med.

    Google Scholar 

  27. Shi C, Gonzalez RS, Zhao Z, Koyama T, Cornish TC, Hande KR, Walker R, Sandler M, Berlin J, Liu EH (2015) Liver metastases of small intestine neuroendocrine tumors: Ki-67 heterogeneity and World Health Organization grade discordance with primary tumors. Am J Clin Pathol 143:398–404

    Article  PubMed  PubMed Central  Google Scholar 

  28. Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Baum RP, Prasad V, Hommann M (2013) Comparing of IRS and Her2 as immunohistochemical scoring schemes in gastroenteropancreatic neuroendocrine tumors. Int J Clin Exp Pathol 5:187–194

    Google Scholar 

  29. Daniel K, Maria A, Amelie L, Isabell L, Stefan S, Luisa P, Merten H, Vikas P, Gerd B, Paul BR (2014) Somatostatin receptor immunohistochemistry in neuroendocrine tumors: comparison between manual and automated evaluation. Int J Clin Exp Pathol 7:4971–4980

    PubMed Central  Google Scholar 

  30. Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C et al (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20:1172–1182

    Article  CAS  PubMed  Google Scholar 

  31. Team R R: A language and environment for statistical computing. (3.3):Vienna, Austria.

  32. Kloppel G (2011) Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer 18(Suppl 1):S1–16

    Article  PubMed  Google Scholar 

  33. Heidari P, Wehrenberg-Klee E, Habibollahi P, Yokell D, Kulke M, Mahmood U (2013) Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization. Cancer Res 73:6865–6873

    Article  CAS  PubMed  Google Scholar 

  34. Nicolas G, Giovacchini G, Muller-Brand J, Forrer F (2011) Targeted radiotherapy with radiolabeled somatostatin analogs. Endocrinol Metab Clin N Am 40:187–204 ix-x

    Article  CAS  Google Scholar 

  35. Oksuz MO, Winter L, Pfannenberg C, Reischl G, Mussig K, Bares R, Dittmann H (2014) Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC? Diagn Interv Imaging 95:289–300

    Article  CAS  PubMed  Google Scholar 

  36. Kwekkeboom DJ, de Herder WW, van Eijck CH, Kam BL, van Essen M, Teunissen JJ, Krenning EP (2010) Peptide receptor radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors. Semin Nucl Med 40:78–88

    Article  PubMed  Google Scholar 

  37. Frilling A, Clift AK (2015) Therapeutic strategies for neuroendocrine liver metastases. Cancer 121:1172–1186

    Article  CAS  PubMed  Google Scholar 

  38. Bodei L, Mueller-Brand J, Baum RP, Pavel ME, Horsch D, O'Dorisio MS, O'Dorisio TM, Howe JR, Cremonesi M, Kwekkeboom DJ et al (2013) The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging 40:800–816

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Korner M, Waser B, Reubi JC (2015) Does somatostatin or gastric inhibitory peptide receptor expression correlate with tumor grade and stage in gut neuroendocrine tumors? Neuroendocrinology 101:45–57

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, 1161 21st Avenue South, C-3321 MCN, Nashville, TN, 37232-2561, USA

    Mongkon Charoenpitakchai, Won Jae Huh & Chanjuan Shi

  2. Department of Surgery, Rocky Mountain Cancer Centers, Denver, CO, 80218, USA

    Eric Liu

  3. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 37232-2561, USA

    Zhiguo Zhao & Tatsuki Koyama

  4. Department of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN, 37232-2561, USA

    Jordan Berlin & Kenneth Hande

  5. Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, Nashville, TN, 37027, USA

    Ronald Walker

Authors
  1. Mongkon Charoenpitakchai
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eric Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhiguo Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tatsuki Koyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Won Jae Huh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Jordan Berlin
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kenneth Hande
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ronald Walker
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Chanjuan Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Chanjuan Shi.

Ethics declarations

The study was reviewed and approved by the Vanderbilt Institutional Review Board. Consent was not required for this study.

Funding

This work was partially supported by NIH/NIDDK DK058404-11 (ZZ and TK), NIH/NCI P50CA095103 (CS), and NCI CA 096625 (EL).

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Charoenpitakchai, M., Liu, E., Zhao, Z. et al. In liver metastases from small intestinal neuroendocrine tumors, SSTR2A expression is heterogeneous. Virchows Arch 470, 545–552 (2017). https://doi.org/10.1007/s00428-017-2093-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00428-017-2093-3

Keywords

Search

Navigation